XUXIN (HONGKONG) BIOTECHNOLOGY CO., LIMITEDHong Kong SAR or China On-site Full Time Associate Skills: Responsibilities of AI Bioinformatics Engineer Position: Develop and implement AI-driven bioinformatics analysis platforms for research and translational applications. Conduct target discovery, molecular simulations, and large language model (LLM) development based on multi-omics data. Requirements: Master’s/Ph. D. degree in Bioinformatics, Computational Biology, or a related field. Familiar with biological sciences; proficiency in Linux systems and programming languages (e.g., Python). Familiarity with neural networks, Transformer architectures, and omics data analysis techniques (e.g., genomics, transcriptomics). At least one high-impact SCI publication in bioinformatics, deep learning, or related areas. Additional Information Job Level Associate Publish Date07/03/2025 Job Ref. No. N/AJob Function Biotechnology Life Science Research & Development (R&D)Company Overview XUXIN (Hong Kong) Biotechnology Co., Limited is a wholly-owned subsidiary established in Hong Kong in 2024 by Reco RNA (Guangzhou) Biotechnology Co., Ltd. The company was founded by a team of scientists led by a Stanford University-trained Ph. D. and senior pharmaceutical executives with extensive experience in managing international and domestic pharmaceutical companies. XUXIN focuses on AI-driven innovative RNA drug development for addressing unmet clinical needs in the treatment of genetic diseases, neurological disorders, and chronic illnesses. The AI model under development will have broad applications in RNA drug design and optimization: It is applicable for optimizing key parameters such as editing efficiency, binding affinity, and off-target effects for RNA editing modules. As the platform evolves, the AI model will also incorporate gene expression profiles, genomic variants, and phenotypic data to predict therapeutic outcomes, enhance precision in RNA drug development, and streamline the RNA drug discovery process. The AI model will be sufficient to support large-scale RNA drug screening and design for a range of diseases, thus significantly reducing time-to-market for novel therapies. #J-18808-Ljbffr